Pharm5 – Details, episodes & analysis

Podcast details

Technical and general information from the podcast's RSS feed.

Pharm5

Elizabeth B. Hearn, PharmD, BCACP

Health & Fitness

Frequency: 1 episode/8d. Total Eps: 59

The top five things happening in pharmacy this week in five minutes or less! Hosted by assistant professor of pharmacotherapy and board certified ambulatory care pharmacist, Dr. Elizabeth B. Hearn.

Site

RSS

Apple

Recent rankings

Latest chart positions across Apple Podcasts and Spotify rankings.

Apple Podcasts

🇫🇷 France - medicine
08/10/2025
#75
🇫🇷 France - medicine
16/09/2025
#87
🇫🇷 France - medicine
15/09/2025
#57

Spotify

No recent rankings available

Shared links between episodes and podcasts

Links found in episode descriptions and other podcasts that share them.

See all

https://natmatch.com/ashprmp/schedule.html
10 shares
https://cnn.it/3ALjKjF
4 shares
https://cnn.it/3olj1id
4 shares

RSS feed quality and score

Technical evaluation of the podcast's RSS feed quality and structure.

See all

RSS feed quality

To improve

Score global : 43%

Publication history

Monthly episode publishing history over the past years.

Year

Latest published episodes

Recent episodes with titles, durations, and descriptions.

See all

Oral treatment for recurrent C Diff, J&J baby powder settlement, Trikafta for 2+ years, and more!

Friday, April 28, 2023 • Duration 04:52

We’ll be taking a break in May, June, and July while our host is on maternity leave. See you again in August!

This week on Pharm5:

Vowst (SER-109) for recurrent C Diff
Trikafta for CF in 2+ years
Mounjaro for weight loss in diabetes
Qalsody accelerated approval for ALS
J&J talc baby powder settlement

Connect with us!

Listen to our podcast: Pharm5
Follow us on Twitter: @LizHearnPharmD

References:

FDA approves first orally administered fecal microbiota product for the prevention of recurrence of Clostridioides difficile infection. U.S. Food and Drug Administration. https://bit.ly/3Li7Cue. Published April 26, 2023. Accessed April 27, 2023.
Feuerstadt P, Louie TJ, Lashner B, et al. Ser-109, an oral microbiome therapy for recurrent clostridioides difficile infection. New England Journal of Medicine. 2022;386(3):220-229. doi:10.1056/nejmoa2106516
Vowst [package insert]. Cambridge, MA: Seres Therapeutics, Inc.; 2023.
FDA approves Trikafta for children ages 2 through 5 years with certain CF mutations. Cystic Fibrosis Foundation. https://bit.ly/44dP3QD. Published April 26, 2023. Accessed April 27, 2023.
Lobo A. FDA expands its approval of Trikafta to cover younger children. Cystic Fibrosis News Today. https://bit.ly/3oSuhG0. Published April 27, 2023. Accessed April 27, 2023.
CFTR modulator therapies. Cystic Fibrosis Foundation. https://bit.ly/3Az4epZ. Accessed April 27, 2023.
Lilly's tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in surmount-2. Eli Lilly and Company. https://bit.ly/3VkD9AE. Published April 27, 2023. Accessed April 27, 2023.
Galvez-Jiminez N, Goyal NA, Cudkowicz ME. Disease-modifying treatment of amyotrophic lateral sclerosis. UpToDate. http://www.utdol.com. Updated May 17, 2022. Accessed May 19, 2022.
Liu A. FDA awards Biogen's ALS Drug Qalsody an accelerated approval, following its experts' feedback this time. Fierce Pharma. https://bit.ly/3VaVwrC. Published April 25, 2023. Accessed April 27, 2023.
FDA approves Qalsody™ (Tofersen) as the first treatment targeting a genetic cause of ALS. PR Newswire: press release distribution, targeting, monitoring, and marketing. https://bit.ly/3ADSe6N. Published April 25, 2023. Accessed April 27, 2023.
Qalsody [package insert]. Cambridge, MA: Biogen, Inc.; 2023.
J&J to retain all talc-related liabilities from litigation in US, Canada. Reuters. https://bit.ly/3HjTS10. Published April 27, 2023. Accessed April 27, 2023.
Spector M, Knauth D. J&J unit files for second bankruptcy to pursue $8.9 billion talc settlement. Reuters. https://bit.ly/426xfoY. Published April 5, 2023. Accessed April 27, 2023.

Read moreCollapse

PREP Act extension, Doxy-PEP for MSM, Medicare covers CGMs, and more!

Friday, April 21, 2023 • Duration 04:48

This week on Pharm5:

PREP act extended to December 2024
Doxy-PEP for MSM
Medicare expands CGM coverage
COVID vaccine changes
DEA Drug Take Back Day

Connect with us!

Listen to our podcast: Pharm5
Follow us on Twitter: @LizHearnPharmD

References:

Fact sheet: HHS announces intent to amend the declaration under the PREP Act for medical countermeasures against COVID-19. HHS.gov. https://bit.ly/3osEGZ4. Published April 14, 2023. Accessed April 20, 2023.
HHS extends PREP act for certain pharmacist and technician services. ASHP. https://bit.ly/3ovmq19. Accessed April 20, 2023.
Luetkemeyer AF, Donnell D, Dombrowski JC, et al. Postexposure doxycycline to prevent bacterial sexually transmitted infections. New England Journal of Medicine. 2023;388(14):1296-1306. doi:10.1056/nejmoa2211934
NIH-funded study finds doxycycline reduces sexually transmitted infections by two-thirds. National Institutes of Health. https://bit.ly/3H2jtvr. Published April 6, 2023. Accessed April 20, 2023.
Glucose Monitor - Policy Article. CMS.gov Centers for Medicare & Medicaid Services. https://bit.ly/3owSyl2. Accessed April 20, 2023.
Tucker ME. Medicare expands CGM coverage to more with type 2 diabetes. Medscape. https://bit.ly/3KR9eet. Published April 17, 2023. Accessed April 20, 2023.
Chen S. Medicare expands CGM coverage for people with type 2 diabetes. diaTribe. https://bit.ly/3AgHLxV. Published April 17, 2023. Accessed April 20, 2023.
Coronavirus (COVID-19) update: FDA authorizes changes to simplify use of bivalent mRNA COVID-19 vaccines. U.S. Food and Drug Administration. https://bit.ly/41HrXQr. Accessed April 20, 2023.
CDC simplifies COVID-19 vaccine recommendations, allows older adults and immunocompromised adults to get second dose of the updated vaccine. Centers for Disease Control and Prevention. https://bit.ly/3V0dxsE. Published April 20, 2023. Accessed April 20, 2023.

OTC Narcan, PBM Transparency Act, rocuronium shortage, & more!

Friday, February 17, 2023 • Duration 04:05

This week on Pharm5:

Narcan possibly OTC soon
Dexcom G7 now available
PBM Transparency Act hearing
Rocuronium shortage
Phase I Rankings now open

Connect with us!

Listen to our podcast: Pharm5
Follow us on Twitter: @LizHearnPharmD

References:

Hoffman J. Narcan is safe to sell over the counter, advisers to the F.D.A. conclude. The New York Times. http://bit.ly/3S2btPf. Published February 15, 2023. Accessed February 16, 2023.
Person, Bhanvi Satija PJ. U.S. FDA panel backs OTC opioid overdose drug, proposes label changes. Reuters. http://bit.ly/3xrx0r5. Published February 16, 2023. Accessed February 16, 2023.
New Dexcom G7 CGM Nick Jonas Super bowl 2023. Dexcom. http://bit.ly/3Is32cU. Accessed February 16, 2023.
Dexcom G7 receives FDA clearance: The most accurate continuous glucose monitoring system cleared in the U.S. Business Wire. https://bit.ly/3UMwMnv. Published December 8, 2022. Accessed February 16, 2022.
Bringing transparency and accountability to Pharmacy Benefit Managers. U.S. Senate Committee on Commerce, Science, & Transportation. http://bit.ly/3YAhjKg. Published February 16, 2023. Accessed February 16, 2023.
FDA drug shortages. FDA Drug Shortages. http://bit.ly/3Ir1kZb. Accessed February 16, 2023.
Drug shortage detail: Rocuronium injection. ASHP. http://bit.ly/3Kat9q3. Accessed February 16, 2023.

2023 Immunization Schedules, NAPLEX/MPJE pass rates, and more!

Friday, February 10, 2023 • Duration 04:08

This week on Pharm5:

Adult Immunization Schedule 2023
Pediatric Immunization Schedule 2023
Rapid acting antidepressant, Zuranolone
2022 NAPLEX/MPJE Pass Rates
State of the Union Address

Connect with us!

Listen to our podcast: Pharm5
Follow us on Twitter: @LizHearnPharmD

References:

Murthy N, Wodi AP, Cineas S, Ault KA. Recommended Adult Immunization Schedule, United States, 2023. https://doi.org/10.7326/M23-0041. Ann Int Med. 2023.
The 5 biggest changes in the 2023 adult vaccine schedules. Medscape. http://bit.ly/40WmmX5. Published February 9, 2023. Accessed February 9, 2023.
Committee on Infectious Diseases. Recommended Childhood and Adolescent Immunization Schedule: United States, 2023. https://doi.org/10.1542/peds.2022-061029. Pediatrics. 2023.
Swift D. AAP approves 2023 Child and adolescent immunization schedule. Medscape. http://bit.ly/3RMFhPD. Published February 9, 2023. Accessed February 9, 2023.
Biogen and Sage Therapeutics announce FDA accepts filing of New Drug Application and grants priority review of Zuranolone in the treatment of major depressive disorder and postpartum depression. Biogen. http://bit.ly/3HR6pbB. Accessed February 9, 2023.
Data & Research. National Association of Boards of Pharmacy. http://bit.ly/40W5qQv. Accessed February 9, 2023.
Aislinn Antrim E. State of the union address focuses on affordable health care, cost of insulin. Pharmacy Times. . Published February 8, 2023. Accessed February 9, 2023.

"Pharmacist shortage," GoodRx in hot water, COVID updates, and more!

Friday, February 3, 2023 • Duration 04:23

This week on Pharm5:

Walmart, CVS Claim Pharmacist Shortage
Changes to Paxlovid, Lagevrio, and COVID vaccines
EzriCare eyedrops linked to bacterial outbreak
New FDA approvals: Jayprica, Orserdu, Jesduvroq
GoodRx sells health info to advertisers

Connect with us!

Listen to our podcast: Pharm5
Follow us on Twitter: @LizHearnPharmD

References:

Valinsky J. CVS and Walmart Cut Pharmacy Hours, close some locations earlier, citing staffing shortage | CNN business. CNN. http://bit.ly/3RpgS2F. Published January 27, 2023. Accessed February 2, 2023.
Keagy J. American Pharmacists Association on move to cut pharmacy hours. American Pharmacists Association. http://bit.ly/3JB0v0Q. Published January 30, 2023. Accessed February 2, 2023.
Paxlovid, Lagevrio prescriptions no longer need a positive COVID-19 test. Becker's Hospital Review. http://bit.ly/3DC3Jh3. Published February 1, 2023. Accessed February 2, 2023.
Fact sheet for healthcare providers: emergency use authorization for Paxlovid. New York, NY: Pfizer. https://bit.ly/3RvXNvO. Revised February 1, 2023. Accessed February 2, 2023.
Fact sheet for healthcare providers: emergency use authorization for Lagevrio (molnupiravir) capsules). Rahway, NJ: Merck & Co. https://bit.ly/3HsLo72. Revised February 1, 2023. Accessed February 2, 2023.
Bulloch M. FDA Advisory Committee vote to simplify covid-19 regimen. Pharmacy Times. http://bit.ly/3jweY3t. Published February 1, 2023. Accessed February 2, 2023.

Amazon's RxPass, Omicron XBB, TidePool Loop, and more!

Friday, January 27, 2023 • Duration 04:27

This week on Pharm5:

Amazon’s RxPass Subscription
Brenzavy (bexagliflozin) for T2DM
Leqimbi (lecanemab) for mild Alzheimer disease
Vaccine efficacy for Omicron XBB
TidePool Loop app cleared by FDA

Connect with us!

Listen to our podcast: Pharm5
Follow us on Twitter: @LizHearnPharmD

References:

Gupta V. Introducing RxPass from Amazon Pharmacy, a $5 prescription subscription that helps prime members who take multiple medications save time and money. US About Amazon. http://bit.ly/3ReGKhE. Published January 24, 2023. Accessed January 26, 2023.
All RxPass medications. http://bit.ly/3kN8628. Accessed January 27, 2023.
FDA grants accelerated approval for Alzheimer's disease treatment. U.S. Food and Drug Administration. http://bit.ly/3HxSkRI. Accessed January 26, 2023.
Lecanemab. Lexi-Drugs. Hudson, OH: Lexicomp, 2015. http://bit.ly/3DeqR4X. Accessed January 26, 2023.
Park B. Brenzavvy approved for adults with type 2 diabetes. MPR. http://bit.ly/3DjPME3. Published January 23, 2023. Accessed January 26, 2023.
Early estimates of bivalent mrna booster dose vaccine effectiveness in preventing symptomatic SARS-COV-2 infection attributable to omicron ba.5– and XBB/XBB.1.5–related sublineages among immunocompetent adults - increasing community access to testing program, United States, December 2022–January 2023. Centers for Disease Control and Prevention. https://bit.ly/3kRkMos. Published January 25, 2023. Accessed January 26, 2023.

Glaspie v. NABP, chlorthalidone v. HCTZ, the end of federal COVID-19 funding, and more!

Friday, December 16, 2022 • Duration 04:39

Thanks to members of Phi Delta Chi's Delta Beta Chapter for creating this episode - Angelica Okinda, Nihitha Nukala, Shannyn Gilchrist-Oates, Hunter Kieltyka, Sydney Thompson, Dylan J. McNutt, Kristopher S. Ingram, Rebecca Nelson, and Emmanuel Rodivera!

This week on Pharm5:

Glaspie v. NABP
Chlorthalidone not superior to HCTZ
Krazati (adagrasib) FDA approval
ASHP reports 20 states prescribing OCP
Federal COVID-19 vaccine funding ends

Connect with us!

Listen to our podcast: Pharm5
Follow us on Twitter: @LizHearnPharmD

References:

Ludens ZD, Glaspie E. In the United States District Court for the Northern District of Illinois. Class Action. https://bit.ly/3V7VhM5. Published November 19, 2022. Accessed December 15, 2022.
@NABP. As you may have heard, 220 candidates who took the NAPLEX between July 30th and October 26th received incorrect exam results. https://bit.ly/3UXHfN3. Posted November 10, 2022. Accessed December 15, 2022.
Ishani A, Leatherman SM, Woods P, et al. Design of a pragmatic clinical trial embedded in the Electronic Health Record: The VA's diuretic comparison project. Contemporary Clinical Trials. 2022;116:106754. doi:10.1016/j.cct.2022.106754
Flack JM, Sica DA, Nesbitt S. Chlorthalidone versus hydrochlorothiazide as the preferred diuretic. Hypertension. 2011;57(4):665-666. doi:10.1161/hypertensionaha.110.164566
Ishani A, Cushman WC, Leatherman SM, Lew RA, et al. Chlorthalidone vs. Hydrochlorothiazide for Hypertension–Cardiovascular Events. 10.1056/NEJMoa2212270.

COVID and monkeypox vaccines, PCAT retirement, and new FDA approvals!

Friday, December 9, 2022 • Duration 04:11

This week on Pharm5:

Bivalent booster for kids
Jynneos protects against monkeypox
Dexcom G7 approved for diabetes
Rezlidhia (olutasidenib) approved for AML
PCAT retirement in 2024

Connect with us!

Listen to our podcast: Pharm5
Follow us on Twitter: @LizHearnPharmD

References:

Coronavirus (COVID-19) update: FDA authorizes updated (bivalent) covid-19 vaccines for children down to 6 months of age. U.S. Food and Drug Administration. https://bit.ly/3UIOuIP. Accessed December 8, 2022.
Webinar November 29, 2022 - flu, RSV, COVID-19 and other respiratory threats this fall and Winter. Centers for Disease Control and Prevention. http://bit.ly/3Bf21AX. Published November 16, 2022. Accessed December 8, 2022.
Reduced risk for Mpox after receipt of 1 or 2 doses of JYNNEOS vaccine compared with risk among unvaccinated persons - 43 U.S. jurisdictions, July 31–October 1, 2022. Centers for Disease Control and Prevention. https://bit.ly/3FzvTdL. Published December 8, 2022. Accessed December 8, 2022.
Dexcom G7 receives FDA clearance: The most accurate continuous glucose monitoring system cleared in the U.S. Business Wire. https://bit.ly/3UMwMnv. Published December 8, 2022. Accessed December 8, 2022.
Center for Drug Evaluation and Research. FDA approves Olutasidenib. U.S. Food and Drug Administration. https://bit.ly/3W2vSo5. Accessed December 8, 2022.
Pharmcas Community. Retirement of the Pharmacy College Admission Test (PCAT). https://bit.ly/3Y9EomW. Published December 6, 2022. Accessed December 8, 2022.

Pharm5 – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Spotify

Shared links between episodes and podcasts

RSS feed quality and score

Publication history

Latest published episodes

Related Shows Based on Content Similarities

Apple Podcasts

Spotify

Related Shows Based on Content Similarities

Pharm5 – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Spotify

Shared links between episodes and podcasts

Other99+

Twitter5

New York Times2

RSS feed quality and score

Publication history

Latest published episodes

Similar podcasts and content

Related Shows Based on Content Similarities

Apple Podcasts

Spotify

Related Shows Based on Content Similarities

Other99+

Twitter5

New York Times2